Wakamoto Pharmaceutical

4512.TPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥9.9bn+27.2% YoY Operating income¥256m—Total assets¥16.5bn+10.0% YoY EPS (basic)¥6.54+253.5% YoY

Full financial history and reports →

Stock price4512 · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, Aug 27 · JST1 filing

15:345% STAKEWakamoto Pharmaceutical · Asset Value Investors Limited · 10.60% → 11.64%+1.04pp

Tue, Mar 24 · JST1 filing

15:36MATERIALWakamoto Pharmaceutical · Change of representative director

Tue, Jan 13 · JST1 filing

15:40MATERIALWakamoto Pharmaceutical · Change in major shareholder

Fri, Jan 9 · JST1 filing

16:135% STAKEWakamoto Pharmaceutical · Asset Value Investors Limited · 9.58% → 10.60%+1.02pp

Thu, May 29 · JST1 filing

15:505% STAKEWakamoto Pharmaceutical · Asset Value Investors Limited · 8.54% → 9.58%+1.04pp

All filings →

Major holders (5%+) · 2

Holder	Stake	Change	Filed
Asset Value Investors Limited	11.64%	+1.04pp	2026-08-27
ROHTO PHARMACEUTICAL CO., LTD.	11.40%	—	2025-02-13

Each holder's own ratio from its most recent large-shareholding report.